From Our Partners

ArtiDock from Receptor.AI: Next-generation AI Docking That Beats DiffDock and AlphaFold-latest

Receptor.AI has announced ArtiDock, the best-in-class model for “AI docking," which predicts the binding poses of small molecule ligands in protein …

Continue ›››

How to Discover a Preclinical Drug Candidate in Two Years

Recent advances in artificial intelligence (AI) has played a pivotal role in optimizing the small-molecule synthesis, standardization, scalability and CRO-based …

Continue ›››

How AI Enables Precision Oncology

Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from …

Continue ›››

How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery

What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific …

Continue ›››

The Power of STB CLOUD in Remote AI Drug Discovery

STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery …

Continue ›››

The State of A.I. Drug Discovery and Its Future: Small Molecules, Vaccines, and Antibodies

Artificial intelligence (A.I.) and big data in a synergistic integration have led to promising results in new drug development by …

Continue ›››

Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung

Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the …

Continue ›››

Powering Cancer Drug Discovery and Development Using the Artificial Intelligence and Machine Learning Platform RADR®

Introduction Glioblastomas (GBM) are devastating brain tumors and rank as one of the most aggressive human cancers with a median …

Continue ›››

Using End-to-End Wet Lab Automation Combined with Machine Learning to Industrialize Drug Discovery

Arctoris is driven by a relentless pursuit to make drug discovery better. An industry where bringing a single drug to …

Continue ›››

Identifying High Impact Tissue Sparing E3 Ligases and Their Binders

There are many drug target classes for which unwanted on-target pharmacology limits clinical application. Understanding E3 tissue expression across both …

Continue ›››

QUAISAR Computational Platform for Designing Targeted Protein Degraders

A key step in the targeted protein degradation (TPD) process is the formation of an induced proximity complex, where a …

Continue ›››

Application of AI-driven Xanthos Platform for Designing Protein Degraders

In contrast to the discovery of "traditional drugs" such as small molecule inhibitors and most biologics, the development of protein …

Continue ›››